Eli Lilly and Company (NYSE:LLY) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on November 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $14.47 during midday trading on Friday, hitting $1,071.35. 5,764,777 shares of the stock were exchanged, compared to its average volume of 4,037,773. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a 50 day moving average price of $956.00 and a 200-day moving average price of $828.10. The stock has a market cap of $1.01 trillion, a P/E ratio of 52.41, a PEG ratio of 1.31 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the firm posted $1.18 EPS. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Orforglipron hit its primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial — patients who switched from Wegovy or Zepbound maintained virtually all prior weight loss; Lilly has filed orforglipron with the FDA for obesity, paving the way for a potential oral alternative to injectables. Lilly PR: Orforglipron Phase 3
• Positive Sentiment: Major outlets reported the trial results and FDA filing, which materially raises the odds Lilly can capture market share from injectable GLP‑1s — an investor-friendly growth thesis if approved and reimbursed. CNBC: Lilly pill maintains weight loss
• Positive Sentiment: Chugai and other partners highlighted positive Phase 3 topline data and Lilly’s FDA filing, reinforcing confidence in regulatory and commercial execution for the oral program. TipRanks: Chugai update on orforglipron
• Positive Sentiment: Bank of America / sell‑side commentary lifted quality/valuation views and flagged material upside tied to oral obesity drug sales (BofA sees multi‑billion dollar potential). That analyst optimism supports near‑term multiple expansion. Benzinga: BofA bullish on Lilly
• Positive Sentiment: Street upgrades continue — Daiwa raised its view on LLY, adding to momentum from bullish coverage and positive earnings/guidance execution. American Banking News: Daiwa upgrade
• Neutral Sentiment: Lilly is advancing other obesity/diabetes assets (e.g., eloralintide into Phase 3), which diversifies long‑term growth but is less likely to move near‑term results. TipRanks: Eloralintide Phase 3
• Neutral Sentiment: Marketing and brand initiatives (e.g., Olympic partnerships) support awareness but have limited immediate financial impact relative to clinical/regulatory news. MMM‑Online: Olympics marketing
• Negative Sentiment: Reuters reported Lilly cut list prices for Mounjaro and Zepbound in Canada by ~20%+, which could pressure revenue per patient in that market and signals payer pricing leverage — a potential headwind if similar moves spread. Reuters: Price cuts in Canada

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $29,000. Finally, Steph & Co. raised its holdings in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LLY shares. Truist Financial upped their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Leerink Partners reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday. Wolfe Research boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,141.73.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.